{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:23:31Z","timestamp":1792002211833,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40256-024-00677-x","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:02:12Z","timestamp":1725969732000},"page":"823-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin in Patients with Venous Thromboembolism using Real-World Data: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"24","author":[{"given":"Walaa A.","family":"Alshahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan S.","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munirah A.","family":"Alkathiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed M.","family":"Alay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman M.","family":"Alabkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A.","family":"Alaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed S.","family":"Al Yami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waad A.","family":"Altayyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamah M.","family":"Alfayez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar S.","family":"Basoodan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaali R.","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"677_CR1","doi-asserted-by":"publisher","unstructured":"Day ISCfWT. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014; 12:1580\u20131590. https:\/\/doi.org\/10.1111\/jth.12698.","DOI":"10.1111\/jth.12698"},{"key":"677_CR2","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/s0140-6736(16)30514-1","volume":"388","author":"M Di Nisio","year":"2016","unstructured":"Di Nisio M, van Es N, B\u00fcller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388:3060\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(16)30514-1.","journal-title":"Lancet"},{"key":"677_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ajh.21917","volume":"86","author":"SB Deitelzweig","year":"2011","unstructured":"Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011;86:217\u201320. https:\/\/doi.org\/10.1002\/ajh.21917.","journal-title":"Am J Hematol"},{"key":"677_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","volume":"20","author":"PL Lutsey","year":"2023","unstructured":"Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20:248\u201362. https:\/\/doi.org\/10.1038\/s41569-022-00787-6.","journal-title":"Nat Rev Cardiol"},{"key":"677_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/13696998.2018.1445635","volume":"21","author":"A Sepassi","year":"2018","unstructured":"Sepassi A, Chingcuanco F, Gordon R, Meier A, Divino V, DeKoven M, et al. Resource utilization and charges of patients with and without diagnosed venous thromboembolism during primary hospitalization and after elective inpatient surgery: a retrospective study. J Med Econ. 2018;21:595\u2013602. https:\/\/doi.org\/10.1080\/13696998.2018.1445635.","journal-title":"J Med Econ"},{"key":"677_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","volume":"41","author":"DM Witt","year":"2016","unstructured":"Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombol. 2016;41:187\u2013205. https:\/\/doi.org\/10.1007\/s11239-015-1319-y.","journal-title":"J Thromb Thrombol"},{"key":"677_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2019","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2019;41:543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405.","journal-title":"Eur Heart J"},{"key":"677_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1565","volume":"369","author":"T McCormack","year":"2020","unstructured":"McCormack T, Harrisingh MC, Horner D, Bewley S. Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing. BMJ. 2020;369: m1565. https:\/\/doi.org\/10.1136\/bmj.m1565.","journal-title":"BMJ"},{"key":"677_CR9","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693\u2013738. https:\/\/doi.org\/10.1182\/bloodadvances.2020001830.","journal-title":"Blood Adv"},{"key":"677_CR10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160:2247\u201359. https:\/\/doi.org\/10.1016\/j.chest.2021.07.056.","journal-title":"Chest"},{"key":"677_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12959-016-0107-z","volume":"14","author":"S Piran","year":"2016","unstructured":"Piran S, Schulman S. Management of venous thromboembolism: an update. Thromb J. 2016;14:23. https:\/\/doi.org\/10.1186\/s12959-016-0107-z.","journal-title":"Thromb J"},{"key":"677_CR12","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342\u201352. https:\/\/doi.org\/10.1056\/NEJMoa0906598.","journal-title":"N Engl J Med"},{"key":"677_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.004450.","journal-title":"Circulation"},{"key":"677_CR14","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"The EINSTEIN Investigators","year":"2010","unstructured":"The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499\u2013510. https:\/\/doi.org\/10.1056\/NEJMoa1007903.","journal-title":"N Engl J Med"},{"key":"677_CR15","doi-asserted-by":"publisher","unstructured":"The EINSTEIN\u2013PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New Engl J Med. 2012;366:1287\u20131297. https:\/\/doi.org\/10.1056\/NEJMoa1113572.","DOI":"10.1056\/NEJMoa1113572"},{"key":"677_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507.","journal-title":"N Engl J Med"},{"key":"677_CR17","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","unstructured":"The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1306638.","journal-title":"N Engl J Med"},{"key":"677_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"issue":"1","key":"677_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jrsm.1316","volume":"10","author":"D Langan","year":"2019","unstructured":"Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. 2019;10(1):83\u20139.","journal-title":"Res Synth Methods."},{"key":"677_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156:787\u20138. https:\/\/doi.org\/10.1001\/jamasurg.2021.0522.","journal-title":"JAMA Surg"},{"key":"677_CR21","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000."},{"key":"677_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11239-017-1578-x","volume":"45","author":"AN Basto","year":"2018","unstructured":"Basto AN, Fewel NP, Vo K, Stock EM, Ta M. Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. J Thromb Thrombol. 2018;45:51\u20135. https:\/\/doi.org\/10.1007\/s11239-017-1578-x.","journal-title":"J Thromb Thrombol"},{"key":"677_CR23","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1160\/th17-03-0210","volume":"117","author":"CI Coleman","year":"2017","unstructured":"Coleman CI, Bunz TJ, Turpie AGG. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thromb Haemost. 2017;117:1841\u20137. https:\/\/doi.org\/10.1160\/th17-03-0210.","journal-title":"Thromb Haemost"},{"key":"677_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4323","volume":"359","author":"M Jun","year":"2017","unstructured":"Jun M, Lix LM, Durand M, Dahl M, Paterson JM, Dormuth CR, et al. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ. 2017;359: j4323. https:\/\/doi.org\/10.1136\/bmj.j4323.","journal-title":"BMJ"},{"key":"677_CR25","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1160\/th16-10-0745","volume":"117","author":"C Sindet-Pedersen","year":"2017","unstructured":"Sindet-Pedersen C, Langtved Pallisgaard J, Staerk L, Gerds TA, Fosb\u00f8l EL, Torp-Pedersen C, et al. Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study. Thromb Haemost. 2017;117:1182\u201391. https:\/\/doi.org\/10.1160\/th16-10-0745.","journal-title":"Thromb Haemost"},{"key":"677_CR26","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/s2352-3026(17)30054-6","volume":"4","author":"TB Larsen","year":"2017","unstructured":"Larsen TB, Skj\u00f8th F, Kj\u00e6ldgaard JN, Lip GYH, Nielsen PB, S\u00f8gaard M. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Lancet Haematol. 2017;4:e237\u201344. https:\/\/doi.org\/10.1016\/s2352-3026(17)30054-6.","journal-title":"Lancet Haematol"},{"key":"677_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11239-018-1661-y","volume":"46","author":"H Badreldin","year":"2018","unstructured":"Badreldin H. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study. J Thromb Thrombol. 2018;46:16\u201321. https:\/\/doi.org\/10.1007\/s11239-018-1661-y.","journal-title":"J Thromb Thrombol"},{"key":"677_CR28","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1055\/s-0038-1668521","volume":"118","author":"NS Roetker","year":"2018","unstructured":"Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam TJ, MacLehose RF. All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism. Thromb Haemost. 2018;118:1637\u201345. https:\/\/doi.org\/10.1055\/s-0038-1668521.","journal-title":"Thromb Haemost"},{"key":"677_CR29","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1055\/s-0038-1673689","volume":"118","author":"D Weycker","year":"2018","unstructured":"Weycker D, Li X, Wygant GD, Lee T, Hamilton M, Luo X, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. Clinical Practice. Thromb Haemost. 2018;118:1951\u201361. https:\/\/doi.org\/10.1055\/s-0038-1673689.","journal-title":"Thromb Haemost"},{"key":"677_CR30","first-page":"245","volume":"38","author":"YM Al Khateep","year":"2019","unstructured":"Al Khateep YM, Zaid NA, Salim OR. Comparative study of safety and effectiveness of rivaroxaban and warfarin in patients with acute deep venous thrombosis. Egypt J Surg. 2019;38:245\u20139.","journal-title":"Egypt J Surg"},{"key":"677_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12959-020-00219-w","volume":"18","author":"OS Costa","year":"2020","unstructured":"Costa OS, Thompson S, Ashton V, Palladino M, Bunz TJ, Coleman CI. Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis. Thromb J. 2020;18:6. https:\/\/doi.org\/10.1186\/s12959-020-00219-w.","journal-title":"Thromb J"},{"key":"677_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ajhp\/zxz307","volume":"77","author":"GK Dawwas","year":"2020","unstructured":"Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. Am J Health Syst Pharm. 2020;77:188\u201395. https:\/\/doi.org\/10.1093\/ajhp\/zxz307.","journal-title":"Am J Health Syst Pharm"},{"key":"677_CR33","doi-asserted-by":"publisher","first-page":"6813492","DOI":"10.1155\/2020\/6813492","volume":"2020","author":"Y Huang","year":"2020","unstructured":"Huang Y, Duan L, He W, Hong C, Guo Y, Wang X, et al. Efficacy and safety of rivaroxaban versus warfarin for the treatment of acute pulmonary embolism: a real-world study. Anal Cell Pathol (Amst). 2020;2020:6813492. https:\/\/doi.org\/10.1155\/2020\/6813492.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"677_CR34","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1253\/circj.CJ-19-0741","volume":"84","author":"CH Lee","year":"2020","unstructured":"Lee CH, Fang CC, Tsai LM, Lin HW, Chen PS, Lin SH, et al. Changing treatment patterns in patients with venous thromboembolism in Taiwan. Circ J. 2020;84:283\u201393. https:\/\/doi.org\/10.1253\/circj.CJ-19-0741.","journal-title":"Circ J"},{"key":"677_CR35","doi-asserted-by":"publisher","first-page":"590","DOI":"10.5603\/AHP.a2021.0085","volume":"52","author":"I Naqvi","year":"2021","unstructured":"Naqvi I, Talib A, Nayema R, Syed M, Ghazanfar R, Fatima S. Length of hospital stay in treatment of venous thromboembolism: do outcomes vary preference of anticoagulant? A retrospective analysis. Acta Haematol Polon. 2021;52:590\u20136.","journal-title":"Acta Haematol Polon"},{"key":"677_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12575","volume":"5","author":"NA Zakai","year":"2021","unstructured":"Zakai NA, Walker RF, MacLehose RF, Koh I, Alonso A, Lutsey PL. Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis. Res Pract Thromb Haemost. 2021;5: e12575. https:\/\/doi.org\/10.1002\/rth2.12575.","journal-title":"Res Pract Thromb Haemost"},{"key":"677_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.121.008005","volume":"14","author":"AC Perino","year":"2021","unstructured":"Perino AC, Fan J, Schmitt S, Guo JD, Hlavacek P, Din N, et al. Anticoagulation treatment and outcomes of venous thromboembolism by weight and body mass index: insights from the veterans health administration. Circ Cardiovasc Qual Outcomes. 2021;14: e008005. https:\/\/doi.org\/10.1161\/circoutcomes.121.008005.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"677_CR38","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jvsv.2022.01.006","volume":"10","author":"A Pham","year":"2022","unstructured":"Pham A, Heib A, Goodman E, Cotto R, Jafari P, Lipsitz E, et al. Warfarin versus direct oral anticoagulants for patients needing distal deep vein thrombosis treatment. J Vasc Surg Venous Lymphat Disord. 2022;10:826-831.e821. https:\/\/doi.org\/10.1016\/j.jvsv.2022.01.006.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"677_CR39","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s12325-023-02440-1","volume":"40","author":"AT Cohen","year":"2023","unstructured":"Cohen AT, Sah J, Dhamane AD, Hines DM, Lee T, Rosenblatt L, et al. Effectiveness and safety of apixaban vs warfarin in patients with venous thromboembolism with risk factors for bleeding or for recurrences. Adv Ther. 2023;40:1705\u201335. https:\/\/doi.org\/10.1007\/s12325-023-02440-1.","journal-title":"Adv Ther"},{"key":"677_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cgh.2022.06.033","volume":"21","author":"AB Ingason","year":"2023","unstructured":"Ingason AB, Hreinsson JP, Agustsson AS, Lund SH, Rumba E, Palsson DA, et al. Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared with direct oral anticoagulants: a population-based propensity-weighted cohort study. Clin Gastroenterol Hepatol. 2023;21:347-357.e310. https:\/\/doi.org\/10.1016\/j.cgh.2022.06.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"677_CR41","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1855\/jmcp.2020.19311","volume":"26","author":"JD Guo","year":"2020","unstructured":"Guo JD, Rajpura J, Hlavacek P, Keshishian A, Sah J, Delinger R, et al. Comparative clinical and economic outcomes associated with warfarin versus apixaban in the treatment of patients with venous thromboembolism in a large U.S. Commercial Claims Database. J Manag Care Spec Pharm. 2020;26:1017\u201326. https:\/\/doi.org\/10.1855\/jmcp.2020.19311.","journal-title":"J Manag Care Spec Pharm"},{"key":"677_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.thromres.2020.11.039","volume":"198","author":"JD Guo","year":"2021","unstructured":"Guo JD, Hlavacek P, Rosenblatt L, Keshishian A, Russ C, Mardekian J, et al. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population. Thromb Res. 2021;198:163\u201370. https:\/\/doi.org\/10.1016\/j.thromres.2020.11.039.","journal-title":"Thromb Res"},{"key":"677_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/ejh.13185","volume":"102","author":"CG Kohn","year":"2019","unstructured":"Kohn CG, Bunz TJ, Beyer-Westendorf J, Coleman CI. Comparative risk of major bleeding with rivaroxaban and warfarin: population-based cohort study of unprovoked venous thromboembolism. Eur J Haematol. 2019;102:143\u20139. https:\/\/doi.org\/10.1111\/ejh.13185.","journal-title":"Eur J Haematol"},{"key":"677_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40360-023-00712-8","volume":"24","author":"E Ramos-Isaza","year":"2023","unstructured":"Ramos-Isaza E, Tuta-Quintero E, Bastidas-Goyes A, et al. Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin\u2014propensity score matching study. BMC Pharmacol Toxicol. 2023;24:77.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"8","key":"677_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.28033","volume":"6","author":"MC Fang","year":"2023","unstructured":"Fang MC, Reynolds K, Fan D, et al. Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism. JAMA Netw Open. 2023;6(8): e2328033.","journal-title":"JAMA Netw Open"},{"key":"677_CR46","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/joim.13712","volume":"294","author":"K Glise Sandblad","year":"2023","unstructured":"Glise Sandblad K, Schulman S, Rosengren A, S\u00f6rbo J, Philipson J, Hansson P-O. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment\u2014a nationwide register-based study. J Intern Med. 2023;294:743\u201360.","journal-title":"J Intern Med"},{"key":"677_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21090","volume":"21","author":"JA Sterne","year":"2017","unstructured":"Sterne JA, Bodalia PN, Bryden PA, Davies PA, L\u00f3pez-L\u00f3pez JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21:1\u2013386. https:\/\/doi.org\/10.3310\/hta21090.","journal-title":"Health Technol Assess"},{"key":"677_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jjcc.2016.07.007","volume":"69","author":"K Senoo","year":"2017","unstructured":"Senoo K, Kondo Y, Miyazawa K, Isogai T, Chun YH, Kobayashi Y. Safety and efficacy of direct oral anticoagulants over warfarin in Japanese patients with acute venous thromboembolism: a meta-analysis. J Cardiol. 2017;69:763\u20138. https:\/\/doi.org\/10.1016\/j.jjcc.2016.07.007.","journal-title":"J Cardiol"},{"key":"677_CR49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2217\/fca-2021-0120","volume":"18","author":"S Deitelzweig","year":"2022","unstructured":"Deitelzweig S, Bergrath E, Fusco MD, Kang A, Savone M, Cappelleri JC, et al. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis. Future Cardiol. 2022;18:393\u2013405. https:\/\/doi.org\/10.2217\/fca-2021-0120.","journal-title":"Future Cardiol"},{"key":"677_CR50","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.2147\/ijgm.S322221","volume":"14","author":"MS Al Yami","year":"2021","unstructured":"Al Yami MS, Alzahrani MY, Alshehri AM, Alshaya OA, Alsubiae NS, Alharbi YM, et al. Real-world effectiveness and safety of apixaban versus warfarin in patients with acute venous thromboembolism: experience of a large tertiary hospital in Saudi Arabia. Int J Gen Med. 2021;14:4031\u20137. https:\/\/doi.org\/10.2147\/ijgm.S322221.","journal-title":"Int J Gen Med"},{"key":"677_CR51","doi-asserted-by":"publisher","first-page":"261s","DOI":"10.1177\/1076029618800806","volume":"24","author":"S Deitelzweig","year":"2018","unstructured":"Deitelzweig S, Guo JD, Hlavacek P, Lin J, Wygant G, Rosenblatt L, et al. Hospital resource utilization and costs associated with warfarin versus apixaban treatment among patients hospitalized for venous thromboembolism in the United States. Clin Appl Thromb Hemost. 2018;24:261s\u20138s. https:\/\/doi.org\/10.1177\/1076029618800806.","journal-title":"Clin Appl Thromb Hemost"},{"key":"677_CR52","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27838","volume":"14","author":"RA Memon","year":"2022","unstructured":"Memon RA, Hamdani SSQ, Usama A, Aisha F, Kundi H, Mathavan M, et al. Comparison of the efficacy and safety of apixaban and warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation: a meta-analysis. Cureus. 2022;14: e27838. https:\/\/doi.org\/10.7759\/cureus.27838.","journal-title":"Cureus"},{"key":"677_CR53","doi-asserted-by":"publisher","first-page":"1086871","DOI":"10.3389\/fsurg.2023.1086871","volume":"10","author":"Z Liu","year":"2023","unstructured":"Liu Z, Song D, Wang L, Wang C, Zhou J, Sun J, et al. Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: a meta-analysis. Front Surg. 2023;10:1086871. https:\/\/doi.org\/10.3389\/fsurg.2023.1086871.","journal-title":"Front Surg"},{"key":"677_CR54","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1182\/bloodadvances.2019000572","volume":"3","author":"MR Aryal","year":"2019","unstructured":"Aryal MR, Gosain R, Donato A, Yu H, Katel A, Bhandari Y, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv. 2019;3:2381\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2019000572.","journal-title":"Blood Adv"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00677-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00677-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00677-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:30:22Z","timestamp":1730305822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00677-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["677"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00677-x","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"22 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Walaa A. Alshahrani, Razan S. Alshahrani, Munirah A. Alkathiri, Saeed M. Alay, Abdulrahman M. Alabkka, Saleh A. Alaraj, Majed S. Al Yami, Waad A. Altayyar, Osamah M. Alfayez, Manar S. Basoodan, Abdulaali R. Almutairi, and Omar A. Almohammed declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The author OAA received funds from the Researcher Supporting Project (number RSP2024R77), King Saud University, Riyadh, Saudi Arabia, to support the publication of this article. The funding agency played no role in designing the study, conducting the analysis, interpreting the data, or writing the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that the article or the supplementary material contain all the data used in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"All listed authors have significantly contributed to the research, providing direct and intellectual input throughout the process. <i>WAA:<\/i> Investigation, resources, data curation, writing\u2014original draft. <i>RSA:<\/i> Investigation, methodology, validation, writing\u2014reviewing and editing. <i>MAA:<\/i> Validation, writing\u2014reviewing and editing. <i>SMA:<\/i> Investigation, resources, data curation, writing\u2014original draft. <i>AMA:<\/i> Investigation, resources, data curation, writing\u2014original draft. <i>SAA:<\/i> Investigation, resources, data curation, writing\u2014original draft. <i>MSA:<\/i> Validation, resources, writing\u2014reviewing and editing. <i>ARA:<\/i> Investigation, methodology, validation, formal analysis, data curation, software, writing\u2014reviewing and editing, supervision. <i>WAA:<\/i> Investigation, resources, data curation. <i>OMA:<\/i> Investigation, methodology, validation, writing\u2014reviewing and editing. <i>MSB<\/i>: Investigation, data curation, writing\u2014reviewing and editing <i>OAA:<\/i> Validation, methodology, validation, supervision, writing\u2014reviewing and editing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}